Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07960613 (Pfizer)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
PF-07960613 is a next-generation nucleoside-modified messenger RNA (modRNA) vaccine candidate developed by Pfizer in collaboration with BioNTech for the prevention of COVID-19. As part of a broader program to develop vaccines with enhanced breadth and durability of protection against SARS-CoV-2 variants, PF-07960613 encodes a modified version of the viral spike protein. The vaccine is encapsulated in lipid nanoparticles (LNPs) to facilitate delivery into host cells, where the mRNA is translated into the target antigen to elicit both neutralizing antibodies and T-cell-mediated immune responses. It is currently undergoing evaluation in Phase 1/2 clinical trials to determine its safety profile and immunogenicity compared to existing COVID-19 vaccines.
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on PF-07960613 (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07960613 (Pfizer).